menu
    • menu
    [{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Altavant Sciences | Covance","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Tryptophan 5-hydroxylase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Altavant Sciences \/ Altavant Sciences | Covance","highestDevelopmentStatusID":"6","companyTruncated":"Altavant Sciences \/ Altavant Sciences | Covance"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Altavant Sciences | Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Tryptophan 5-hydroxylase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Altavant Sciences \/ Altavant Sciences | Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Altavant Sciences \/ Altavant Sciences | Parexel"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Tryptophan 5-hydroxylase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Altavant Sciences \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"Altavant Sciences \/ PPD"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Tryptophan 5-hydroxylase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Altavant Sciences \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"Altavant Sciences \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Altavant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Inapplicable","moa":"||IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Altavant Sciences \/ Altavant Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Altavant Sciences \/ Altavant Sciences"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Enzyvant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"Allogeneic Processed Thymus Tissue","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altavant Sciences \/ Enzyvant Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Altavant Sciences \/ Enzyvant Therapeutics"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ALTA-2530","moa":"||IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ALTA-2530","moa":"||IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altavant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Altavant Sciences \/ Sumitovant Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Altavant Sciences

    Menu

    Altavant Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Altasciences Company Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the He...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 06, 2023

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Altasciences Company Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Single and Multiple Dose of Rodatristat Ethyl in Healthy Adult Subjects to Evaluate the Effect of Food and S...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 13, 2023

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Processed Thymus Tissue,Inapplicable

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Sponsor : Enzyvant Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Enzyvant Announces Merger with Altavant

                            Details : RETHYMIC® (allogeneic processed thymus tissue-agdc) is a novel one-time tissue-based regenerative therapy used for immune reconstitution in pediatric patients with congenital athymia.

                            Product Name : Rethymic

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 12, 2022

                            Lead Product(s) : Allogeneic Processed Thymus Tissue,Inapplicable

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Sponsor : Enzyvant Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rodatristat Ethyl,Ambrisentan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Altavant Sciences Presents Data Showing Potential For Combination Of Rodatristat Ethyl And Ambrisentan In Mode...

                            Details : RVT-1201 (rodatristat ethyl) is a tryptophan hydroxylase inhibitor designed to reduce body’s peripheral production of serotonin, in preclinical study comparing rodatristat ethyl monotherapy and in combination with ambrisentan, in an animal model of PAH...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 05, 2022

                            Lead Product(s) : Rodatristat Ethyl,Ambrisentan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTA-2530,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Sumitovant Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Altavant Sciences to Present Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candid...

                            Details : Results of in vivo preclinical studies measuring lung distribution of aerosolized ALTA-2530, an IL-1 receptor antagonist (IL-1Ra) in development for treatment of bronchiolitis obliterans syndrome, a life-threatening form of CLAD.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 25, 2022

                            Lead Product(s) : ALTA-2530,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Sumitovant Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALTA-2530,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Altavant Sciences Presented Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candida...

                            Details : Results of in vivo studies presented at ISHLT demonstrate that aerosolized ALTA-2530 achieved distribution to distal regions of lung. In separate in vitro studies, ALTA-2530 demonstrated a significantly greater binding affinity for IL-1 type 1 receptor.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 05, 2022

                            Lead Product(s) : ALTA-2530,Inapplicable

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Altavant Sciences | Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multiple-Ascending Dose in Japanese Patients Bridging Study

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 04, 2021

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Altavant Sciences | Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Altavant Sciences | Covance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics and Excretion of Oral [14C]-Rodatristat Ethyl

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 16, 2021

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Altavant Sciences | Covance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Altavant Sciences Reports Rodatristat Ethyl PK/PD Analysis at ATS Supporting Doses Selected for Phase 2b ELEVA...

                            Details : ELEVATE 2 will test the ability of rodatristat to reduce the peripheral production of serotonin through its unique mechanism of tryptophan hydroxylase (TPH) inhibition in order to improve PAH symptoms.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 20, 2021

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Altavant Sciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 15, 2021

                            Lead Product(s) : Rodatristat Ethyl,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth